TNXP
$14.24+0.68 (+5.01%)
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United ...
Recent News
Tonix prices 615,025 shares at $16.26 in registered direct offering
Tonix Pharmaceuticals (TNXP) entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase price of $16.259 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.001 per share exercise price of each pre-funded warran
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Tonix Pharmaceuticals Holding Corp (TNXP) Showcases Promising TNX-801 Vaccine Data
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is one of the top long-term biotechnology stocks to buy. On October 17, Tonix Pharmaceuticals (NASDAQ:TNXP) presented encouraging preclinical data for its investigational mpox and smallpox vaccine candidate, TNX-801, at the World Vaccine Congress Europe 2025. The live, attenuated horsepox-based vaccine elicited strong immune responses, provided long-term protection, and demonstrated […]
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain?
The new treatment may only offer modest benefits, but could gain traction in a market with few other options.
FDA Approves New Fibromyalgia Drug, But Tonix Shares Slide
Tonix Pharmaceuticals reported late Friday that the Food and Drug Administration had approved its Tonmya treatment for fibromyalgia. Fibromyalgia, a condition affecting 10 million adults in the U.S., mainly women, causes chronic pain and fatigue. Tonix shares opened down 14% following the FDA news and a Monday morning press conference.